Hts Biopharma Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
- Paid Up Capital ₹ 0.90 M
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
- Revenue Growth 34.70%
- Profit Growth 173.93%
- Ebitda 17.46%
- Net Worth 21.63%
- Total Assets 6.90%
About Hts Biopharma
Hts Biopharma Private Limited (HBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 16 April 2012 and has a history of 12 years and nine months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹2.00 Cr.
Srinivas Chaduvu, Surendar Velagapuri, and Neelima Veldi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232TG2012PTC080323
-
Company No.
080323
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Apr 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Hts Biopharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinivas Chaduvu
|
Director | 20-Jan-2017 | Current |
|
Surendar Velagapuri
|
Director | 20-Jan-2017 | Current |
|
Neelima Veldi
|
Director | 21-Sep-2013 | Current |
Financial Performance of Hts Biopharma.
Hts Biopharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 34.7% increase. The company also saw a substantial improvement in profitability, with a 173.93% increase in profit. The company's net worth Soared by an impressive increase of 21.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hts Biopharma?
In 2020, Hts Biopharma had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Synventia Pharma Private LimitedSurendar Velagapuri is a mutual person
Charges (Loans)
₹20.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2021 | Others | ₹2.00 Cr | Open |
How Many Employees Work at Hts Biopharma?
Unlock and access historical data on people associated with Hts Biopharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hts Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hts Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
